Oculis Holding (NASDAQ:OCS) Full Year 2022 Results
Key Financial Results
-
Net loss: CHF38.7m (loss widened by 109% from FY 2021).
-
CHF12.95 loss per share (further deteriorated from CHF6.68 loss in FY 2021).
OCS Products In Clinical Trials
-
Phase II: 4.
-
Phase III: 2.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Oculis Holding shares are up 9.2% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 6 warning signs for Oculis Holding you should be aware of, and 5 of them are significant.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here